Save up -80% on Insulin Glargine

Note: this is a drug discount program, not an insurance plan.

RX BIN: 015558
Group ID: DDN6600
Card Holder ID: DDN6600

Pharmacists and Patients support.

2018 Price of Insulin Glargine

Lantus 100 unit/ml cartridge



* price without discount in nearest pharmacy. Price may vary.

Claim your free Insulin Glargine coupon

We offer free Insulin Glargine coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Insulin Glargine every time. What are you waiting for? Claim your prescription drug card now!

Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time

Insulin Glargine volume of distribution

About RX24Drugs

Discount Cards 16,000+

Clients Benefit 29%

Total savings $4,735,080

What is Insulin Glargine

Insulin glargine is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. It is an analogue of human insulin made by replacing the asparagine residue at position A21 of the A-chain with glycine and adding two arginines to the C-terminus (positions B31 and 32) of the B-chain. The resulting protein is soluble at pH 4 and forms microprecipitates at physiological pH 7.4. Small amounts of insulin glargine are slowly released from microprecipitates giving the drug a long duration of action (up to 24 hours) and no pronounced peak concentration.

Insulin Glargine mechanism of action

Insulin glargine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism. Insulin glargine is completely soluble at pH 4, the pH of administered solution, and has low solubility at physiological pH 7.4. Upon subcuteous injection, the solution is neutralized resulting in the formation of microprecipitates. Small amounts of insulin glargine are released from microprecipitates giving the drug a relatively constant concentration over time profile over 24 hours with no pronounced peak. This release mechanism allows the drug to mimic basal insulin levels within the body.

Dosage forms of Insulin Glargine

Form Route Strength
Solution for injection Subcutaneous use 100 Units/ml
Solution for injection to 80 unit injection) Subcutaneous use 100 Units/ml
Solution subcutaneous 100 unit
Prescription Generics


International Brands



Insulin Glargine (rDNA origin) Insulin glargine recombinant


Eli Lilly Canada Inc

CAS number






Affected organisms

Humans and other mammals

Indication of Insulin Glargine

For the treatment of Type 1 or 2 diabetes mellitus in patients over 17 years old who require a long-acting (basal) insulin for the control of hyperglycemia. May be used in pediatric patients with Type 1 diabetes mellitus who require a long-acting (basal) insulin for glycemic control.

Toxicity of Insulin Glargine

Inappropriately high dosages relative to food intake and/or energy expenditure may result in severe and sometimes prolonged and life-threatening hypoglycemia. Neurogenic (autonomic) signs and symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea and tingling. Neuroglycopenic signs and symptoms of hypoglycemia include difficulty concentrating, lethargy/weakness, confusion, drowsiness, vision changes, difficulty speaking, headache, and dizziness. Mild hypoglycemia is characterized by the presence of autonomic symptoms. Moderate hypoglycemia is characterized by the presence of autonomic and neuroglycopenic symptoms. Individuals may become unconscious in severe cases of hypoglycemia. Other adverse events that may occur include allergic reaction, injection site reaction, lipodystrophy, pruritis, and rash.

RX24 Drugs Disclaimer: before buying a Insulin Glargine on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.

Get lower price on Insulin Glargine now!

Leave a Review